NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in agilon health, inc. ("agilon health, inc." or the "Company") (NYSE: AGL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of agilon health, inc. investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agilon ...

NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus issue ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Stride - Stride, an education technology company, allegedly inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and provided a poor customer experience, leading to higher withdrawal rates and lower conversion rates [4]. - The company claimed to be experiencing growth and strong demand for its products, which contrasts with the allegations of inflated metrics [4]. Group 3: Stock Performance Impact - On September 14, 2025, a report of the fraud allegations caused Stride's stock to drop by $18.60 per share, or over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, or more than 54%, from $153.53 to $70.05, with an estimated impact of 10,000-15,000 fewer enrollments [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a 180-day cliff method for reserving accounts [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fermi Inc. (NASDAQ: FRMI): (i) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with Fermi’s October 2025 initial public offering (the “IPO”); and/or (ii) securities between October 1, 2025 and December 11, 2025, inclusive (the “Class Period”), have until March 6, 2026 to seek appointment as lead plaintiff of the Fermi ...

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the "Class Period†), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health and certain of Ardent Health' ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after transitioning to a new revenue accounting system [3]. - The new accounting system, Kodiak RCA net revenue platform, allows for more precise determination of accounts receivable collectability and recognizes reserves earlier in an account's life cycle compared to the previous framework [3]. - Ardent also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [3]. - Additionally, the company recorded a $54 million increase in professional liability reserves related to recent settlements and ongoing litigation, influenced by broader industry trends [3]. - Following these announcements, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [3].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - Jefferies downgraded First Solar from Buy to Hold on January 7, 2026, citing lowered guidance, significant de-bookings, and margin compression throughout 2025 [2] - Following the downgrade, First Solar's stock price decreased by $27.67, or 10.29%, closing at $241.11 per share on January 7, 2026 [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - AST SpaceMobile, Inc. is under investigation for potential securities fraud and unlawful business practices, coinciding with a recent downgrade by Scotiabank which has negatively impacted the company's stock price [1][2]. Group 1: Company Investigation - Pomerantz LLP is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding possible securities fraud or other unlawful business practices by the company and its officers [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance and Analyst Downgrade - On January 7, 2026, Scotiabank downgraded AST SpaceMobile to a "Sell" rating, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [2]. - Following the downgrade, AST's stock price decreased by $11.76 per share, representing a 12.06% decline, closing at $85.73 per share on the same day [2].